IP Library Granted Patent US 8,022,194
Granted Patent B2
US 8,022,194 · App. 12/803,261 · Granted Sep 20, 2011

2′-nitrobenzyl-modified ribonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,022,194
App. No.
12/803,261
Granted
Sep 20, 2011
Kind
B2
Abstract

This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.

Claims (29)

1. A ribonucleotide having a formula PM-SM-BASE wherein PM is a phosphate moiety, SM is a ribose, BASE is a pyrimidine or purine, and wherein said ribose comprises a reversible chain terminating moiety at a 2′ position in said ribose, wherein the reversible chain terminating moiety is selected from the group consisting of a 2-Nitrobenzyl group, a Desyl group and a p-hydroxyphenacyl caging group.

2. The ribonucleotide of claim 1 wherein the BASE is selected from the group consisting of adenine, guanine, cytosine and uracil.

3. The ribonucleotide of claim 1 which is a ribonucleoside 5 ′-phosphate.

4. The ribonucleotide of claim 1 wherein said reversible chain terminating moiety is connected to said ribose by a reversible linkage.

5. The ribonucleotide of claim 4 wherein said reversible linkage is a bond that is cleavable by electromagnetic radiation, chemical treatment, or a combination thereof.

6. The ribonucleotide of claim 5 wherein said electromagnetic radiation is light.

7. The ribonucleotide of claim 1 wherein the reversible chain terminating moiety is a 2-Nitrobenzyl group.

8. The ribonucleotide of claim 1 wherein the reversible chain terminating moiety is a Desyl group.

9. The ribonucleotide of claim 1 wherein the reversible chain terminating moiety is a p-hydroxyphenacyl caging group.

10. The ribonucleotide of claim 1 wherein said ribonucleotide is labeled with a detectable label.

11. The ribonucleotide of claim 10 wherein said detectable label is a moiety is selected from the group consisting of green fluorescent protein, blue fluorescent protein, red fluorescent protein, beta-galactosidase, chloramphenicol acetyltransferase, beta-glucoronidase, luciferases, beta-lactamase, digoxygenin, fluorescent dye molecule, fluorescein, alkaline phosphatase and horse radish peroxidase.

12. The ribonucleotide of claim 10 wherein said detectable label may be removed by photobleaching.

13. The ribonucleotide of claim 10 wherein said detectable label is connected to the ribonucleotide by a reversible linkage.

14. A method of producing a reversibly terminating ribonucleoside comprising:

(a) providing a ribonucleoside having a formula SM-BASE wherein SM is a ribose, BASE is a pyrimidine or purine, wherein the ribonucleoside comprises a detectable label; and

(b) attaching a reversible chain terminating moiety at a 2′ position of said ribose, wherein said reversible chain terminating moiety is selected from the group consisting of a 2-Nitrobenzyl group, a Desyl group and a p-hydroxyphenacyl caging group.

15. A method of sequencing a target nucleic acid comprising:

(a) elongating a primer which is complexed with a target nucleic acid to form an incorporated ribonucleotide with a RNA polymerase and at least one first species of ribonucleotide having the formula PM-SM-BASE wherein PM is a phosphate moiety, SM is a ribose, BASE is a pyrimidine or purine, wherein said ribose comprises a chain terminating moiety connected by a reversible linkage at a 2′ position of said ribose, wherein said reversible chain terminating moiety is selected from the group consisting of a 2-Nitrobenzyl group, a Desyl group and a p-hydroxyphenacyl caging group, and wherein the at least one first species of ribonucleotide comprises a detectable label; and

(b) detecting said incorporated ribonucleotide to determine a sequence of said target nucleic acid.

16. The method of claim 15 further comprising:

(c) removing said chain terminating moiety of said incorporated ribonucleotide by breaking said reversible linkage;

(d) repeating steps (a), (b) and (c) with at least one second species of ribonucleotide having the formula PM-SM-BASE wherein PM is a phosphate moiety, SM is a ribose, BASE is a pyrimidine or purine, wherein said ribose comprises a chain terminating moiety connected by a reversible linkage at a 2′ position of said ribose, wherein said reversible chain terminating moiety is selected from the group consisting of a 2-Nitrobenzyl group, a Desyl group and a p-hydroxyphenacyl caging group.

17. The method of claim 15 wherein said complex between said primer and said target nucleic acid is formed by hybridization or synthesis by RNA polymerase.

18. The method of claim 15 wherein said RNA polymerase is a phage-encoded RNA polymerase selected from the group consisting of T3 RNA polymerase, T7 RNA polymerase and SP6 RNA polymerase.

19. The ribonucleotide of claim 1 which is a ribonucleoside 5′-diphosphate.

20. The ribonucleotide of claim 1 which is a ribonucleoside 5′-triphosphate.

21. The ribonucleotide of claim 1 , wherein the BASE is adenine or guanine, and wherein the PM is a monophosphate, diphosphate, or triphosphate moiety.

22. The ribonucleotide of claim 1 , wherein the BASE is uracil or cytosine, and wherein the PM is a monophosphate, diphosphate, or triphosphate moiety.

23. The ribonucleotide of claim 13 , wherein the reversible linkage is a bond that is cleavable by electromagnetic radiation, chemical treatment, or a combination thereof.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
CHANGE OF NAME Recorded Sep 30, 2010
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 025066/0515 →
CERTIFICATE OF MERGER Recorded Sep 30, 2010
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 025066/0614 →
CHANGE OF NAME Recorded Sep 30, 2010
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO, INC.
Reel/Frame 025066/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: PIEPENBURG, OLAF; STEMPLE, DEREK L.; ARMES, NIALL A.
To: ASM SCIENTIFIC, INC.
Reel/Frame 025062/0490 →